Specific Billing J-Code Issued for Trogarzo® by Center for Medicare and Medicaid Services
MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab-uiyk) injection has been assigned a specific J-Code. The new code will come into effect as of January 1, 2019.
J-Codes are developed and issued by the Centre for Medicare and Medicaid Services as part of the Healthcare Common Procedure Coding System (HCPCS) for reporting medical procedures and services.
The code number assigned to Trogarzo® is J-1746. Physicians will be able to use this specific code to submit claims for Trogarzo® to private and public payers.
“Obtaining a J-Code greatly facilitates administrative procedures for physicians and their staff as it standardizes the whole process from claim submission to payment. It is an integral part of any drug reimbursement strategy. This is yet another important milestone reached for Trogarzo® and it should play a part in supporting sales growth,” said Luc Tanguay, President and CEO, Theratechnologies Inc.